Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-08-21
2004-11-16
Chang, Ceila (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S144000, C514S307000
Reexamination Certificate
active
06818651
ABSTRACT:
USE OF THE INVENTION
The invention relates to novel phosphodiesterase inhibitors which are used in the pharmaceutical industry for producing drugs.
KNOWN TECHNICAL BACKGROUND
Journal of Medicinal Chemistry 1979, Vol. 22, No. 4, pp. 348-352 describes, inter alia, 6,7-dimethoxy-1-phenyl-3,4-dihydroisoquinolines which inhibit cAMP phosphodiesterases better than does the non-specific PDE inhibitor theophylline. In International Patent Application WO 99/44609 fused piperidine substituted arylsulfonamides are disclosed which are said to have potent activity in the treatment of Type II diabetes and obesity.
REFERENCES:
patent: 6043263 (2000-03-01), Bar et al.
patent: 0 490 823 (1992-06-01), None
patent: 0 664 289 (1995-07-01), None
patent: 94/10118 (1994-05-01), None
patent: 89/08830 (1998-03-01), None
patent: 98/55481 (1998-12-01), None
patent: 99/44609 (1999-09-01), None
Walker, K.A., et al. “1-(4-Aminobenzyl)- and 1-(4-Aminophenyl) isoquinoline Derivatives: Synthesis and Evaluation as Potential Irreversible Cyclic Nucleotide Phosphodiesterase Inhibitors”, Journal of Medicinal Chemistry , vol. 26, No. 2, pp. 174-181, 1983.*
Caplus AN: 1999:123896, abstract of Fuhrmann, et al “Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells,” American Journal of Respiratory Cell and Molecular Biology (1999), 20(2), 292-302.*
Walker, K.A., et al., “1—(4-Aminobenzyl)—and 1—(4-Aminophenyl) isoquinoline Derivatives: Synthesis and Evaluation as Potential Irreversible Cyclic Neucleotide Phosphodiesterase Inhibitors”,Journal of Medicinal Chemistry, vol. 26, No. 2, pp. 174-181, (1983).
Han, P., et al., “Alternative Splicing of the High Affinity CAMP-Specific Phosphodiesterase (PDE7A) mRNA in Human Skeletal Muscle and Heart”,Journal of Biological Chemistry, vol. 272, No. 26, pp. 16152-16157, (1997).
Li, L., et al., “CD3- and CD28-Dependent Induction of PDE7 Required for T Cell Activation”, Science, vol. 283, pp. 848-851, (Feb. 5, 1999).
Sasaki, T., et al., “Identification of Human PDE7B, a cAMP-Specific Phosphodiesterase”,Biochemical and Biophysical Research Communications, vol. 271, No. 3, pp. 575-583, (2000).
St. Georgiev, V., et al., “Drug-Induced Modifications of the Immune Response. 1. Substituted 1-Phenylisoquinolines”,Journal of Medicinal Chemistry, vol. 22, No. 4, pp. 348-352, (1979).
Michaeli, T., et al., “Isolation and Characterization of a Previously Undetected Human cAMP Phosphodiesterase by Complementation of cAMP Phosphodiesterase-deficientSaccharomyces cerevisiae”, The Journal of Biological Chemistry, vol. 268, No. 17, pp. 12925-12932, (Jun. 15, 1993).
Grundler Gerhard
Hatzelmann Armin
Schmidt Beate
Stadlwieser Josef
Sterk Geert Jan
Altana Pharma AG
Coppins Janet L.
Juneau Todd L.
McGee Sheldon M.
Nath & Associates PLLC
LandOfFree
(Dihydro) isoquinoline derivatives as phosphodiesterase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (Dihydro) isoquinoline derivatives as phosphodiesterase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (Dihydro) isoquinoline derivatives as phosphodiesterase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3328864